Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.560
+0.010 (0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.610
+0.050 (3.21%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Lineage Cell Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $6.25, which forecasts a 300.64% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $9.00.
Price Target: $6.25 (+300.64%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +476.92% | Apr 28, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +156.41% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +476.92% | Mar 24, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +92.31% | Mar 6, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +28.21% | Feb 9, 2026 |
Financial Forecast
Revenue This Year
30.48M
from 14.56M
Increased by 109.40%
Revenue Next Year
15.22M
from 30.48M
Decreased by -50.06%
EPS This Year
-0.06
from -0.28
EPS Next Year
-0.08
from -0.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 60.8M | 27.8M | ||||||
| Avg | 30.5M | 15.2M | ||||||
| Low | 8.3M | 5.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 317.7% | -9.0% | ||||||
| Avg | 109.4% | -50.1% | ||||||
| Low | -43.2% | -82.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.12 | 0.02 | ||||||
| Avg | -0.06 | -0.08 | ||||||
| Low | -0.14 | -0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.